Showing Results for: “exercise”

For people with type 2 diabetes (T2D) and chronic kidney disease (CKD), canagliflozin, an oral, sodium-glucose co-transporter-2 (SGLT2) inhibitor, has a renal- and cardiovascular-protective effect in reducing the progression of kidney impairment, according to the results of the CREDENCE trial presented today in a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. In the first of several renal outcomes studies of SGLT2s, the landmark Canagliflozin and Renal Events in Diabetes with Established Nephropathy

Data Indicates How Changes to Public Health Recommendation on BPA has Potential to Decrease Diabetes Risk A new study reveals the benefits of reducing exposure to a common chemical for reducing the risk of diabetes. The findings are the first to provide evidence that BPA administration may increase type 2 diabetes risk and were presented as an Oral Presentation - Presidents' Select Abstract as well as a Symposium at the 84 th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Bisphenol A (BPA) is an industrial chemical used to make polycarbonate plastic and epoxy

The American Diabetes Association® (ADA) is honored to announce the recipients of the 2021 National Scientific and Health Care Achievement Awards. The awards recognize academics, health care providers and educators who have contributed to tangible advances in the field of diabetes care and research. Each of these leaders have unwavering dedication to achieving the mission of the ADA: life free of diabetes and all its burdens. “I am thrilled to recognize the eight remarkable individuals receiving the ADA’s National Scientific and Health Care Achievement Awards,” said Tracey D. Brown, Chief

VERTIS-CV trial of SGLT2 inhibitor evaluated medication’s cardiovascular safety in patients with type 2 diabetes and heart disease The sodium glucose co-transporter 2 (SGLT2) inhibitor ertugliflozin does not impact the likelihood of heart attack, stroke, or cardiac death in patients with type 2 diabetes (T2D) and established cardiovascular (CV) disease, according to data presented today. Research also showed the rate of hospitalization for heart failure was lower among study participants treated with ertugliflozin. The study was highlighted during the “Results of the eValuation of

Our Ask the Experts series is designed to help people with diabetes tackle commonly faced issues by providing a community where individuals can ask questions of our diabetes experts and hear from others who might share similar experiences.

Christel is a Los Angeles based speaker, writer, diabetes coach and diabetes advocate. She has been living with type 1 diabetes since 1997 and at an early stage decided that it wasn’t going to slow her down. Her motto is “There is Nothing You Can’t do With Diabetes”. She writes about how to be Fit With Diabetes on DiabetesStrong.com. She also coaches people with diabetes from across the globe, online and in-person, and supports them in meeting their health and fitness goals. Christel holds an MBA in Finance & Strategy and an ISSA Personal Trainer certification with specialization in Fitness

The first sub-analysis of renal data from the Dapagliflozin Effect on Cardiovascular Events Thrombolysis In Myocardial Infarction (DECLARE-TIMI 58) trial indicates that dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor, reduced the progression of kidney disease or renal death in patients with type 2 diabetes (T2D). The initial results from the trial, the first cardiovascular outcome study to enroll a large cohort of patients with diabetes risk factors for Atherosclerotic Cardiovascular Disease (ASCVD) and a large number of patients with diabetes with known ASCVD, were

Results of the PIONEER 6 trial indicate oral semaglutide is safe for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk, according to results announced at the symposium titled “Oral Semaglutide—The PIONEER Program Trials” today at the American Diabetes Association’s® (ADA) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Oral semaglutide reduced cardiovascular death and all-cause mortality by nearly 50 percent, based on median follow up of 15.9 months. PIONEER 6 was conducted across 21 countries and included 3,183 participants who were randomized

The Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial has found dulaglutide, an injectable, glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrates superiority in the reduction of cardiovascular events for a broad range of people living with type 2 diabetes (T2D), according to research presented today at a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. The REWIND trial is the first study to include a majority of participants (69%) with no history of cardiovascular disease (CVD) at enrollment. Additionally, the